Last checked at 
| Thursday 31 January | |
| Redhall Group | Full Year Results |
| Royal Dutch Shell | Full Year Results |
| Angle | Half Year Results |
| Rank Group | Half Year Results |
| Alumasc Group | Half Year Results |
| Renishaw | Half Year Results |
| Ergomed | Trading Statement |
| BT Group | Q3 Results |
| Premier Vetinary Group | Full Year Results |
| Evraz | Trading Statement |
| Polymetal International | Q4 Production |
| Diageo | Half Year Results |
| Britvic | Trading Statement |
| Dairy Crest Group | Trading Statement |
| DiscoverIE Group | Trading Statement |
| ScS Group | Trading Statement |
| 3i Group | Trading Statement |
| T Clarke | Trading Statement |
| Eaton Group | Full Year Results |
| Unilever | Full Year Results |
| Gattaca | Trading Statement |
| Primary Health Properties | Full Year Results |
| Friday 1 February | |
| Glencore | Full Year Production |
| Euromoney Institutional Investor | Trading Statement |
| TalkTalk Telecom Group | Q3 Results |
| Monday 4 February | |
| Ryanair Holdings | Q3 Results |
| Tuesday 5 February | |
| St Modwen | Full Year Results |
| RM | Full Year Results |
| BP | Full Year Results |
| Ocado Group | Full Year Results |
| Mattioli Woods | Half Year Results |
| Wednesday 6 February | |
| GlaxoSmithKline | Full Year Results (at 1200 GMT) |
| Barratt Developments | Half Year Results |
| Frontier Developments | Half Year Results |
| Electrocomponents | Trading Statement |
| CYBG | Trading Statement |
| Redrow | Half Year Results |
| Victrex | Trading Statement |
| Severn Trent | Trading Statement |
| S&U | Trading Statement |
12 Feb 2024 07:21
GSK gets FDA fast track for chronic hepatitis B treatment
(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).
Read more